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he Evolving Role of Glycoprotein IIb/IIIa Inhibitors
n the Setting of Percutaneous Coronary Intervention
trategies to Minimize Bleeding Risk and Optimize Outcomes
lias B. Hanna, MD,* Sunil V. Rao, MD,† Steven V. Manoukian, MD‡
orge F. Saucedo, MD§
ew Orleans, Louisiana; Durham, North Carolina; Nashville, Tennessee;
nd Oklahoma City, Oklahoma
he use of glycoprotein IIb/IIIa inhibitors (GPI) reduces ischemic events in patients undergoing percuta-
eous coronary intervention (PCI). However, the same properties that confer this beneﬁt lead to an
ncreased bleeding risk. Recent studies have shown a less robust net clinical beneﬁt of GPI in the cur-
ent era of routine thienopyridine and direct thrombin inhibitor use. To optimize the net clinical bene-
t of GPI, these agents need to be selectively used in patients most likely to beneﬁt from their anti-
schemic effect, namely patients undergoing PCI for non–ST-segment elevation myocardial infarction,
elect patients undergoing primary PCI, and select patients undergoing PCI without appropriate pre-
oading with a thienopyridine. Moreover, strategies to minimize bleeding should be applied in these
atients and include shorter GPI infusions (in some patients), dose adjustments of heparin and GPI,
areful access site management with more frequent use of the transradial approach, use of smaller
heaths, and identiﬁcation of patients at high bleeding risk. This review provides an update of the cur-
ent literature that supports these measures, an insight on the tailored use of GPI, and a potential di-
ection for future research addressing combined antithrombotic therapies. (J Am Coll Cardiol Intv
010;3:1209–19) © 2010 by the American College of Cardiology Foundationt
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ilycoprotein IIb/IIIa inhibitors (GPI) are potent
arenteral inhibitors of platelet aggregation. Three
gents are available—abciximab, eptifibatide, and
irofiban—and have been studied across the spec-
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eptember 13, 2010, accepted September 15, 2010.rum of acute ischemic heart disease as well as for
lective and primary percutaneous coronary inter-
ention (PCI) (1–12). The use of all 3 agents in the
etting of PCI has been associated with a signifi-
ant reduction in both short- and long-term events
ompared with unfractionated or low-molecular-
eight heparin alone. Indeed, a 35% to 50%
eduction in major adverse cardiovascular ischemic
vents was reported in low-, intermediate-, and
igh-risk patients undergoing PCI including pa-
ients with stable coronary artery disease (CAD)
1,3,4), patients presenting with non–ST-segment
levation acute coronary syndrome (NSTE-ACS)
5,7,8), particularly patients with elevated troponin
evels (5,12), and patients presenting with ST-
egment elevation myocardial infarction (STEMI)
9–11) (Tables 1, 2, and 3). Notably, this reduction
n events was mainly driven by a reduction in
eriprocedural myocardial infarctions, including
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1210arge or Q-wave myocardial infarctions, but there was no
ortality reduction. Furthermore, a meta-analysis suggested
hat the use of GPI in NSTE-ACS was associated with a
ortality reduction in diabetic patients, but this was not
onfirmed in a randomized trial (13). All of these studies
emonstrated that the risk of bleeding, measured in a variety
f ways, was higher with the addition of GPI to standard
herapy; however, the lack of other therapeutic options and
he high rate of adverse outcomes in both the acute coronary
yndrome (ACS) and PCI settings made for an acceptable
rade-off between the benefit of reduced ischemic events and
he risk of increased bleeding.
Stenting was not routinely performed in these early
tudies, and patients were not pre-treated with thienopyri-
dines. As the therapeutic arma-
mentarium of ischemic heart
disease has evolved, the utility of
GPI has become less clear in a
variety of clinical settings. The
purpose of this review is to sum-
marize the data reducing the role
of GPI to a select population in
the current era, review strategies
for reducing the bleeding risk
associated with GPI, and de-
velop a proposal for what role
GPI should play in the modern
era.
Bleeding Risk Associated
With GPI
Whereas ischemic events were
strikingly reduced with abcix-
imab in the EPIC (Evaluation of
c7E3 for the Prevention of Isch-
emic Complications) trial, TIMI
(Thrombolysis In Myocardial
Infarction) major bleeding risk
was similarly increased (7% for
lacebo vs. 14% for abciximab, p  0.001). However, when
djusted-dose heparin and early sheath removal were im-
lemented, GPI use was associated with a smaller (1%)
bsolute increase in major bleeding in some studies (4,5,8),
nd no significant increase in major bleeding in other
tudies (2,3,6,7). Transfusion requirements and TIMI mi-
or bleeding remained higher with GPI. Of note, the TIMI
cale may underestimate rates of clinically important bleed-
ng complications, and TIMI minor bleeding has been
ssociated with over a 50% increase in the adjusted rate of
eath or myocardial infarction (MI) (14). Thus, significant
leeding associated with GPI may be more common than
bbreviations
nd Acronyms
CS  acute coronary
yndrome(s)
CT  activated clotting
ime
AD  coronary artery
isease
rCl  creatinine clearance
PI  glycoprotein IIb/IIIa
nhibitor(s)
I  myocardial infarction
STE-ACS  non–ST-
egment elevation acute
oronary syndrome(s)
STEMI  non–ST-segment
levation myocardial
nfarction
CI  percutaneous
oronary intervention
TEMI  ST-segment
levation myocardial
nfarction
IMI  Thrombolysis In
yocardial Infarctioneported in these early trials. sAs described in many PCI trials, most major bleeding
ccurs at the femoral access site (1,5). In fact, groin
ematoma and retroperitoneal hemorrhage constituted 60%
o 80% and 5% to 10% of major bleeding events, respec-
ively, whereas gastrointestinal bleeding and intracranial
leeding constituted 15% and 2% of major bleeding
pisodes, respectively. Thus, a safer vascular access strategy
ill potentially attenuate the bleeding risk associated with
PI.
volution of PCI Pharmacotherapy:
iminishing Role of Traditional GPI Dosing
nd Current Indications
s opposed to the pivotal GPI trials (1–11), studies per-
ormed in the current era of routine stenting and thienopy-
idine therapy have not consistently shown a net clinical
enefit with GPI, that is, a benefit on the composite of
eath, MI, revascularization, and major bleeding (Table 4).
fter pre-loading with 600 mg of clopidogrel at least 2 h
efore elective PCI, the ISAR-REACT (Intracoronary Stent-
ng and Antithrombotic Regimen: Rapid Early Action for
oronary Treatment) trial indicated that the addition of
bciximab to unfractionated heparin in low-risk patients un-
ergoing elective PCI did not further reduce ischemic compli-
ations (15); this was further expanded to elective PCI in
iabetic patients in the ISAR-SWEET (Is Abciximab a
uperior Way to Eliminate Elevated Thrombotic Risk in
iabetics) trial (16). In both studies, bleeding rates were higher
ith GPI, therefore shifting the traditional benefit-risk ratio
way from supporting their routine use in elective PCI.
urthermore, in the case of STEMI, the BRAVE-3 (Bavarian
eperfusion Alternatives Evaluation-3) trial (17) showed that
he addition of abciximab to heparin in patients undergoing
rimary PCI and pre-loaded with 600 mg of clopidogrel in the
mergency department did not reduce infarct size or improve
linical outcomes. Previously, the CADILLAC (Controlled
bciximab and Device Investigation to Lower Late Angio-
lasty Complications) trial had shown that patients presenting
ith STEMI and undergoing stenting did not achieve the
ame marked benefit with abciximab as patients undergoing
ngioplasty did (10). Accordingly, the above-mentioned data
uestioned the value of GPI in both elective PCI and primary
CI. However, in the ISAR-REACT 2 trial, the tailored use
f GPI for high-risk NSTE-ACS patients, particularly pa-
ients with elevated troponin levels, was beneficial despite
tenting and pre-loading with clopidogrel and provided a
ubstantial clinical benefit without significantly increasing ma-
or or minor bleeding rates (18). Thus, this trial identified a
opulation in which GPI use is still warranted. In addition, the
se of GPI in patients undergoing an elective PCI for stable
AD, but not adequately pre-loaded with thienopyridines, stilleems reasonable (19).
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1211Newer oral antiplatelet therapies, such as prasugrel and
icagrelor, have not been studied in the setting of elective
CI, but they have shown a benefit over clopidogrel in the
etting of NSTE-ACS and STEMI managed invasively
20,21). In the TRITON–TIMI-38 (Trial to Assess Im-
rovement in Therapeutic Outcomes by Optimizing Plate-
et Inhibition with Prasugrel) trial of 13,608 patients with
CS undergoing PCI, 55% of the patients received GPI.
he benefit of prasugrel over clopidogrel was consistent
mong patients who did or did not receive GPI, and the
elative increase of major or minor bleeding with prasugrel
ersus clopidogrel was not significantly different in patients
ho were or were not treated with GPI (22). This estab-
ished the benefit of prasugrel even in the setting of potent
latelet inhibition with GPI. Similarly, the benefit and
afety of ticagrelor versus clopidogrel was not altered in
atients receiving GPI (21). However, whereas the utility of
dding the potent and prompt platelet inhibitors prasugrel
Table 1. Major Studies Addressing GPI Use in Patients Undergoing PCI (El
Thienopyridine Pre-Loading
Study
(Year) (Ref. #) GPI n
Routine
Stenting
(% Stent Use)
Appropriate
Thienopyridine
Pre-Loading
Thienopyrid
Therapy Aft
PCI
EPIC
(1994) (1)
Abciximab 2,099 No (2%) No N/A
EPILOG
(1997) (2)
Abciximab 2,792 No (15%) No N/A
EPISTENT
(1998) (3)
Abciximab 2,399 Yes (100%) No Yes
ESPRIT
(2000) (4)
Eptiﬁbatide 2,064 Yes (95%) No Yes
*TIMI major bleeding is defined as intracranial hemorrhage or 5 g/dl decrease in the hemoglobin co
decrease in the hemoglobin concentration in case of overt hemorrhage.†In EPILOG trial, patients ra
versus 3.7%, p 0.001.
ACS acute coronary syndrome(s); GPI glycoprotein IIb/IIIa inhibitor; N/A not available; NS
UFH unfractionated heparin.
Table 2. Major Studies Addressing GPI Use in Patients With ACS, a Propor
Appropriate Thienopyridine Pre-Loading
Study
(Year) (Ref. #) GPI n
% Undergoing
PCI
Routine
Stenting in
the PCI
Subgroup
(% Stent Use)
Thienopy
Pre-Loa
CAPTURE
(1997) (5)
Abciximab 1,560 98% No (2%) No
RESTORE
(1997) (6)
Tiroﬁban 2,212 100% No (2.5%) No
PRISM-PLUS
(1998) (7)
Tiroﬁban 1,560 30% No (2%) No
PURSUIT
(1998) (8)
Eptiﬁbatide 10,948 24% (50%) No
*In CAPTURE trial, the benefit of GPI was limited to patients with elevated troponin (death or MI at
troponin was not elevated).MImyocardial infarction; other abbreviations as in Table 1.r ticagrelor to GPI has been investigated, the benefit and
afety of adding GPI therapy to prasugrel or ticagrelor have
ot been evaluated yet and merit investigation.
In addition to antiplatelet therapy, anticoagulants have
lso undergone significant evolution and available options
ow include low-molecular-weight heparins (both subcuta-
eous and intravenous), synthetic indirect factor Xa inhib-
tors, and direct thrombin inhibitors. The agent that has
een most studied directly against a GPI-based strategy is
he direct thrombin inhibitor bivalirudin. Unlike unfrac-
ionated and low-molecular-weight heparins, bivalirudin
oes not activate platelets. The REPLACE-2 (Randomized
valuation of PCI Linking Angiomax to Reduced Clinical
vents) trial (23) compared a strategy of bivalirudin plus
rovisional GPI to a strategy of unfractionated heparin plus
outine GPI in 6,000 patients undergoing elective PCI.
he primary end point of 30-day death, MI, target vessel
evascularization, and major bleeding was similar between
Indication or ACS) Before the Era of Routine Stenting and Appropriate
ACS
GPI vs. Placebo
Death or MI
at 30 Days
TIMI Major
Bleeding*
TIMI Minor
Bleeding*
42% 6.6% vs. 9.6%,
p  0.01
14% vs. 7%,
p  0.001
N/A
46% 4% vs. 9.1%,
p  0.001
2% vs. 3.1%,
p  NS in low-dose UFH†
4% vs. 3.7%,
p  NS in low-dose UFH†
36% 5.2% vs. 10.2%,
p  0.001
1.5% vs. 2.2%,
p  NS
2.9% vs. 1.7%,
p  NS
13% 6.4% vs. 10.2%,
p  0.0014
1% vs. 0.4%,
p  0.027
2.8% vs. 1.7%,
p  NS
ation. TIMI minor bleeding is defined as 4 g/dl decrease in the hemoglobin concentration or 3 g/dl
ed to GPI high-dose UFH had increasedminor bleeding events in comparisonwith placebo: 7.4%
nificant; PCI percutaneous coronary intervention; TIMI Thrombolysis InMyocardial Infarction;
f Whom Underwent PCI, Before the Era of Routine Stenting and
Thienopyridine
Therapy After
PCI
%
Elevated
Troponin
GPI vs. Placebo
Death or MI at
30 Days
TIMI Major
Bleeding
TIMI Minor
Bleeding
N/A 31% 4.8% vs. 9%,
p  0.003*
3.8% vs. 1.9%,
p  0.04
4.8% vs. 2%,
p  0.008
N/A 33% 5.1% vs. 6.3%,
p  0.1
2.4% vs. 2.1%,
p  0.67
N/A
N/A 45% 8.7% vs. 12%,
p  0.004
1.4% vs. 0.8%,
p  0.23
N/A
N/A 45% 14.2% vs. 15.7%,
p  0.004
3% vs. 1.3%,
p  0.001
11.1% vs. 4.7%,
p  0.001
: 5.8% with GPI vs. 19.6% with placebo if troponin elevated; 5.2% with GPI vs. 4.9% with placebo ifective
ine
er
%
ncentr
ndomiz
nonsigtion o
ridine
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30 days
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1212he 2 strategies. This noninferiority was driven by a signif-
cant reduction in major and minor bleeding with bivaliru-
in that came at the expense of a slight and nonsignificant
ncrease in periprocedural MI rate. Similarly, in the open
abel ACUITY (Acute Catheterization and Urgent Inter-
ention Strategy) trial of patients with intermediate-to
igh-risk NSTE-ACS randomized to bivalirudin alone,
ivalirudin plus GPI, or heparin (either unfractionated or
ow-molecular-weight) plus GPI, there was a trend toward
reduction of ischemic events in the GPI arms, particularly
n the absence of thienopyridine pre-loading (24). Again, an
ncreased risk of major bleeding counterbalanced the anti-
schemic benefit of GPI therapy. This pattern held also in
he HORIZONS-AMI (Harmonizing Outcomes with Re-
ascularization and Stents in Acute Myocardial Infarction)
rial that compared bivalirudin to heparin plus GPI in the
etting of primary PCI after preloading with 300 to 600 mg
Table 3. Major Studies Addressing GPI Use in Patients Undergoing Primary
Study
(Year) (Ref. #) GPI n % Stent
Thienopyridi
Before or Im
After
ADMIRAL
(2001) (9)
Abciximab 300 92% No
CADILLAC
angioplasty
arms (2002) (10)
Abciximab 1,046 0% Ye
CADILLAC stent
arms (2002) (10)
Abciximab 1,036 100% Ye
ON-TIME 2
(2008) (11)
Tiroﬁban 984 90% Ye
* In theON-TIME2 trial, patientswere pre-loadedwith 600mgof clopidogrel before arrival to the card
before cardiac catheterization. No loading dose of thienopyridine was administered in the ADMIRA
GUSTO (Global Use of Strategies to OpenOccluded Coronary Arteries) trial criteria were used to defi
reduced the primary end point of residual ST-segment deviation 1 h after PCI but did not improve T
TVR target vessel revascularization; other abbreviations as in Tables 1 and 2.
Table 4. Randomized Trials of GPI Therapy During PCI in the Context of Ro
Study
(Year) (Ref. #) n Study Population
% Complex
(Type B2/C)
Coronary
Lesions
%
Diabe
ISAR-REACT
(2004) (15)
2,159 Stable CAD 65% 21
ISAR-SWEET
(2004) (16)
701 Stable CAD diabetes 68% 100
BRAVE-3
(2009) (17)
800 STEMI — 19
ISAR-REACT 2
(2006) (18)
2,022 ACS 1 troponin in 51% 80% 25
*See TIMI bleeding definition in Table 1. †In the BRAVE-3 trial, abciximabwas not associatedwith a r
emergency department. ‡In patients with elevated troponin values, event rates with GPI versus p
placebo: 4.6% versus 4.6%, p 0.99.CAD coronary artery disease; STEMI ST-segment elevation myocardial infarction; other abbreviationf clopidogrel in the emergency department; patients in the
ivalirudin arm had significantly less bleeding, but a signif-
cantly higher rate of acute stent thrombosis (25). Interest-
ngly however, in the HORIZONS-AMI trial, the rate of
tent thrombosis at 30 days was not significantly different
etween the 2 arms and bivalirudin was associated with a
ower 30-day and 1-year mortality that may have been
elated to the bleeding reduction (25,26). Thus, although
he role of GPI has been questioned in patients presenting
ith STEMI and receiving heparin (17), this role is further
educed in patients receiving bivalirudin. The American
ollege of Cardiology guidelines currently give a Class IIa
ecommendation for the use of GPI at the time of primary PCI
n select patients with STEMI, particularly patients with a
arge thrombus burden or those who have not received ade-
uate thienopyridine loading (27).
for STEMI
ding
tely
GPI vs. Placebo
Death, MI, Urgent
TVR at 30 Days
Major
Bleeding†
Minor or Moderate
Bleeding†
6.0% vs. 14.6%,
p  0.01
0.7% vs. 0%,
p  NS
35.3% vs. 12.1%,
p  0.004
4.8% vs. 8.3%,
p  0.02
0.4% vs. 0.6%,
p  NS
2.3% vs. 2.5%,
p  NS
4.4% vs. 5.7%,
p  NS
0.8% vs. 0.2%,
p  NS
4.3% vs. 2.5%,
p  NS
7% vs. 8.2%,
p  NS‡
4% vs. 2.9%,
p  NS
6.1% vs.4.4%,
p  NS
eterization laboratory. In CADILLAC trial, 300mgof clopidogrel or 500mgof ticlopidinewere given
TIMI criteria were used to definedmajor andminor bleeding in ADMIRAL and ON-TIME 2 trials, and
r andmoderate bleeding in CADILLAC trial. ‡In the ON-TIME 2 trial, the high-bolus dose of tirofiban
grade or clinical outcomes.
Stenting and Adequate Thienopyridine Pre-Loading
GPI vs. Placebo
Death/MI/Urgent
Vessel
Revascularization at
30 Days
TIMI Major
Bleeding*
TIMI Minor
Bleeding*
% Patients
Requiring
Transfusion
4% vs. 4%,
p  NS
1% vs. 1%,
p  NS
2% vs. 2%,
p  NS
2% vs. 1%,
p  0.007
5.7% vs. 4.3%,
p  0.39
1.1% vs. 0.9%,
p  NS
3.4% vs. 1.4%,
p  0.09
2.3% vs. 0.6%,
p  0.11
4.7% vs. 3.5%,
p  NS†
1.8% vs. 1.8%,
p  NS
3.7% vs. 1.8%,
p  0.06
3% vs. 3.3%,
p  NS
8.9% vs. 11.9%,
p  0.03‡
1.4% vs. 1.4%,
p  NS
4.2% vs. 3.3%,
p  NS
2.5% vs. 2%,
p  NS
n in infarct size (the primary end point). Patients were pre-loadedwith 600mg of clopidogrel in the
13.1% versus 18.3%, p  0.02. In patients without troponin elevation, event rates with GPI versusPCI
ne Loa
media
PCI*
s
s
s
iac cath
L trial. †
nemajo
IMI flowutine
tes
%
%
%
%
eductio
lacebo:s as in Tables 1, 2, and 3.
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1213urrent indications for GPI use. In summary, the anti-
schemic value of GPI seems currently limited to 4 sub-
roups of patients: 1) patients with non–ST-segment ele-
ation myocardial infarction (NSTEMI) undergoing PCI
18), particularly if they are not receiving bivalirudin, or if
hey are receiving bivalirudin but are not adequately pre-
oaded with a thienopyridine, as recommended by the
merican College of Cardiology guidelines (24,28); 2)
atients having thrombotic complications or large side-
ranch closure or unsealed dissection during any PCI
erformed for stable or unstable CAD, whether bivalirudin
s used or not (GPI were used for bailout in 7% and 9% of
atients randomized to bivalirudin in the REPLACE-2 and
CUITY trials, respectively); 3) select patients with
TEMI, particularly those not pre-loaded with a thienopy-
idine in the emergency department or those with a large
hrombus burden; 4) patients undergoing ad hoc PCI for
table or unstable CAD and not adequately pre-loaded with
thienopyridine (19). In fact, studies that did not show a
enefit of GPI in elective PCI had mandated appropriate
lopidogrel pre-loading and there is currently not enough
vidence that supports omitting GPI in patients receiving
eparin and not adequately pre-loaded with a thienopyri-
ine (15,16,19). However, if bivalirudin is the anticoagulant
sed in elective PCI, GPI may be omitted regardless of
hienopyridine pre-loading (29); as opposed to ACS, the
omparable effectiveness of bivalirudin and heparin plus
PI in elective PCI was not influenced by clopidogrel
re-treatment (29). Also, GPI may be omitted in ad hoc
lective PCI if a rapid-onset and potent oral P2Y12 receptor
ntagonist is loaded during PCI, but this strategy has yet to
e tested.
On the other hand, if hyporesponsiveness to clopidogrel
r aspirin is suspected clinically or on the basis of platelet
unction or genetic testing, GPI may have a role even in
Table 5. Measures That Reduce Bleeding Risk With GPI
Dosage and infusion
● Bolus-only strategy or reduction of infusion duration
● Careful selection of upstream therapy in acute coronary syndromes limited to patie
and who are at the highest spectrum of risk
● Heparin dose adjustment to obtain ACT 250 s during PCI (starting bolus 50 U/k
● Eptiﬁbatide and tiroﬁban infusion dose adjustment in patients with creatinine clear
Patient selection
● Avoidance of GPI in patients older than 75 years and in patients at high bleeding r
● Targeting patients with NSTEMI undergoing PCI (particularly if not receiving bivalir
Access selection and management
● Use of transradial approach
● Use of smaller sheath size
● Prompt sheath removal
● Avoidance of venous sheath placement in case of femoral access
● Use of vascular closure devices (possibly)
ACT activating clotting time; other abbreviations as in Tables 1, 2, 3, and 4.atients undergoing PCI for stable CAD. In the 3T/2R wTailoring Treatment With Tirofiban in Patients Showing
esistance to Aspirin and/or Resistance to Clopidogrel)
tudy, patients undergoing PCI who were poor responders
o aspirin, clopidogrel, or both who were treated with
irofiban compared to placebo had a significant reduction in
he 30-day risk of major adverse cardiovascular events (3.8%
s. 10.7%, p  0.031), without an increase in bleeding (30).
ith further study, expanded use of bedside and laboratory
latelet function testing, and wider use of genetic testing,
he role of GPI in these situations will become better
efined.
Because a robust relationship between major bleeding and
ncreased mortality and morbidity has been reported in
everal analyses, the reduction of bleeding risk has become a
rimary target for improving PCI outcomes (31,32). There-
ore, it is reasonable to better define strategies of GPI
dministration that would reduce bleeding risk in the 4
ubgroups of patients who benefit from GPI, particularly
atients with NSTEMI. Several potential options are avail-
ble and are discussed herein (Table 5).
uration of Infusion of GPI After PCI:
he Appropriateness of Bolus-Only or
hort-Infusion Strategy
urrently, on the basis of the EPIC and ESPRIT (Novel
osing Regimen of Eptifibatide in Planned Coronary Stent
mplantation) trials, it is recommended to administer a 12-h
nfusion of abciximab and an 18- to 24-h infusion of
ptifibatide, respectively, after PCI. In the EPIC trial, an
bciximab bolus followed by a 12-h infusion resulted in a
5% reduction in the rate of death, MI, or unplanned
evascularization at 30 days compared with unfractionated
eparin alone (1). By contrast, patients receiving bolus-only
o have not received thienopyridine loading
50 and 30 ml/min, respectively
r if receiving bivalirudin but not adequately pre-loaded with a thienopyridine)nts wh
g)
ance 
isk
udin oere protected for the first 6 h only; end points measured at
3
p
m
t
a
d
r
f
r
P
d
l
e
i
B
c
w
s
s
r
c
e
M
t
e
i
c
a
4
o
p
p
a
s
t
t
w
i
r
9

r
t
l
G
u
c
a
t
p
P
w
b
r
p
t
t
w
n
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 2 , 2 0 1 0
D E C E M B E R 2 0 1 0 : 1 2 0 9 – 1 9
Hanna et al.
Optimize GPI Therapy
12140 days demonstrated no difference between bolus-only and
lacebo because of ongoing ischemic events beyond 6 h,
ainly driven by acute vessel closure. However, in the EPIC
rial, thienopyridine therapy was not used and only balloon
ngioplasty was performed. Routine stenting with optimal
eployment technique and coverage of dissection planes
educes the prothrombotic stimuli and may obviate the need
or prolonged GPI infusion. However, due to the concern
aised by the EPIC trial, subsequent trials of abciximab in
CI generally used bolus and 12-h infusion regimens
espite routine stenting and thienopyridine therapy. Simi-
arly, large trials of eptifibatide did not attempt to reduce or
liminate the infusion.
Few studies have specifically addressed the issue of the
nfusion duration in the modern era (Table 6) (33–35). The
RIEF-PCI (Brief Infusion of Eptifibatide Following Per-
utaneous Coronary Intervention) trial randomized patients
ho received eptifibatide bolus therapy and underwent
uccessful PCI with stenting to either a standard (18 h) or
horter (2 h) infusion of eptifibatide (33). All patients
eceived appropriate clopidogrel therapy before or at the
onclusion of PCI. Whereas 32% of patients had ACS with
levated troponin level, most patients had stable CAD.
oreover, patients with visible thrombus, unsealed dissec-
ion, coronary slow flow, or loss of major side branches were
xcluded. Compared with the standard infusion, the shorter
nfusion was associated with a similar incidence of peripro-
edural myonecrosis and adverse ischemic events at 30 days
nd a significantly lower incidence of major bleeding (1% vs.
.2%, p  0.02).
In the EASY (Early Discharge After Transradial Stenting
Table 6. Studies Comparing a Bolus-Only Strategy or a Short Infusion of GP
Study
(Year) (Ref. #) Study Type GPI Type
Study
Population
B2/C Coron
Lesion*
(%)
BRIEF PCI
(2009) (33)
RCT, 624
patients
Eptifbatide ACS (53%) or
stable CAD;
32% positive
troponin
63%
EASY
(2006) (34)
RCT, 1,005
patients
Abciximab ACS or stable
CAD;
20% positive
troponin
47%
Kini et al.
(2008) (35)
Retrospective
analysis,
2,629
patients
Eptiﬁbatide
(72%)
or abciximab
(28%)
ACS (39%) or
stable CAD;
14% positive
troponin
80%
*Coronary lesions defined according to lesion classification of American College of Cardiology/Ame
(600 mg2 h or 300 mg6 h or 75 mg4 days before PCI [33]; 300 mg12 h before PCI [34] ; 30
criteria. Major bleeding intracranial, intraocular, or retroperitoneal hemorrhage; clinically overt blo
of at least 2 U of packed red blood cells or whole blood. Minor bleeding clinically overt bleeding
RCT randomized controlled trial; other abbreviations as in Tables 1, 2, 3, 4, and 5.f Coronary Arteries) trial by Bertrand et al. (34), 1,005 tatients who received a bolus of abciximab during an uncom-
licated transradial PCI were randomly allocated to either an
bciximab bolus-only strategy and same-day discharge, or to a
tandard 12-h abciximab infusion and overnight hospitaliza-
ion. Only 20% of patients had an elevated troponin level at the
ime of the procedure. The bolus-only strategy was noninferior
ith respect to the 30-day occurrence of death or adverse
schemic events. Major bleeding was low in both groups, likely
elated to the use of the radial access site. Of note, more than
0% of patients in the EASY trial had received clopidogrel
12 h before the procedure.
These findings are similar to those reported in a large
etrospective single-center analysis (35). A major limitation of
hese studies is that they compared short-length with full-
ength regimens of GPI, rather than a short-length regimen of
PI with placebo. Because most of these patients were
ndergoing elective PCI for stable CAD and because in the
urrent era, GPI are mainly beneficial in NSTEMI, there was
questionable need for GPI in most of these patients. Thus,
his strategy needs to be adequately studied in NSTEMI and
otentially in patients with stable CAD undergoing ad hoc
CI without clopidogrel pre-loading, where a bolus of GPI
ith a truncated infusion may be enough to bridge the gap
etween PCI and the 2-to-8-h time it takes clopidogrel to
each an adequate antiplatelet effect (this theory is yet un-
roven). The newer P2Y12 receptor antagonists, prasugrel or
icagrelor, which induce a much higher and consistent inhibi-
ion of platelet activity coupled with a prompt onset of activity
ithin 30 min of administration, may further influence any
eed for GPI, more so prolonged GPI infusions, but this needs
h Long Standard Infusions
Duration of
Infusion
Adequate
Clopidogrel
Load
Before PCI†
(%)
Bolus-Only or Short Infusion
vs. Prolonged Infusion
Death/MI/
Urgent TVR
at 30 Days
Major
Bleeding
Risk‡
Minor
Bleeding
Risk‡
2 h vs. 18 h 70% 4.8% vs. 4.5%,
p  1.0
1% vs. 4.2%,
p  0.02
17.6% vs. 21.2%,
p  0.31
olus-only vs.
12 h
92% 1.4% vs. 1.8%,
p  NS
0.8% vs. 0.2%,
p  NS
N/A
olus-only vs.
12–18 h
54% 3.2% vs. 3%,
p  0.73
0.8% vs. 1.6%,
p  0.09
1.1% vs. 2.2%,
p  0.03
art Association. †The definition of appropriate clopidogrel load before PCI varied between studies
3 h before PCI (35)). ‡Major and minor bleeding risks were defined according to REPLACE-2 study
resulting in a decrease in hemoglobin3 g/dl; any decrease in hemoglobin4 g/dl; or transfusion
not meet major bleeding criteria.I Wit
ary

B
B
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od loss
that dido be tested prospectively (36,37).
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1215PI Dose Adjustment
eing renally cleared, eptifibatide and tirofiban infusion
ates should be reduced by 50% if creatinine clearance
CrCl) is 50 or 30 ml/min, respectively, while main-
aining the same bolus dose (38). In addition, eptifibatide
s contraindicated in patients on dialysis (39). By con-
rast, abciximab does not require dose adjustment with
enal failure. Data from moderate-to high-risk PCI
atients with NSTE-ACS treated with eptifibatide in the
ROTECT-TIMI 30 (Randomized Trial to Evaluate
he Relative Protection Against Post-PCI Microvascular
ysfunction and Post-PCI Ischemia Among Anti-
latelet and Anti-Thrombotic Agents) trial showed that
he lack of adjustment of the maintenance infusion
ccurred in 45% of patients with CrCl 50 ml/min and
as associated with a high rate of bleeding complications
20%); in fact, no major or minor bleeding event occurred
mong patients with reduced CrCl who received the
educed-dose infusion (40). Consistent with these find-
ngs, data from the CRUSADE (Can Rapid Risk Strat-
fication of Unstable Angina Patients Suppress Adverse
utcomes With Early Implementation of the ACC/
HA Guidelines) registry showed that excess dosing of
ptifibatide and tirofiban occurs in 27% of patients
reated with GPI, mainly in women, older patients, small
atients, or patients with renal insufficiency (38). Excess
osing was associated with a 17.5% rate of major bleed-
ng, a 36% increase in the adjusted rate of major bleeding,
nd a 50% increase in mortality. Furthermore, data from
he National Cardiovascular Data Registry (NCDR)-CathPCI
egistry indicated that the use of eptifibatide in dialysis
atients was associated with increased in-hospital bleeding
nd mortality risk (39). By contrast, abciximab seems
elatively safe in advanced renal failure (41).
In aggregate, these data suggest that the risks associated
ith GPI can be mitigated in patients with chronic kidney
isease. All patients undergoing PCI need to have CrCl
ssessed, and, if eptifibatide or tirofiban are used, their
osages need to be adjusted accordingly.
mpact of age and sex. Several analyses have shown that
lder patients have an increased bleeding risk with GPI.
n a meta-analysis by Boersma et al. (12), the benefit of
PI decreased with advancing age, with a nonsignificant
reatment effect in patients 60 years of age. Addition-
lly, in a pre-specified subgroup analysis of ACUITY
rial, the benefit of bivalirudin monotherapy over com-
ined therapy with GPI in terms of the number needed to
reat to prevent 1 bleeding event was particularly high in
atients older than 75 years of age (42). These data
uggest that the risk may outweigh the benefit in most
atients older than 75 years of age, and, if used, the GPI
ose should be adjusted and the infusion shortened or
liminated. uResults from the CRUSADE initiative indicate that
omen with ACS had higher rates of major bleeding than
en among patients treated with GPI (15.7% vs. 7.3%,
 0.0001) and among patients not treated with GPI
8.5% vs. 5.4%, p  0.0001) (43). Treated women were also
ore likely to receive excess dosing of GPI than men
46.4% vs. 17.2%, p  0.0001) were, and bleeding risk
ttributable to excess dosing was much higher in women
25.0% vs. 4.4%).
nticoagulation Dose Adjustment
he EPILOG (Evaluation of PTCA to Improve Long-
erm Outcome by c7E3 GP IIb/IIIa Receptor [abciximab]
lockade) trial randomly assigned 2,799 low-risk patients to
lacebo plus standard-dose, weight-adjusted heparin (100
/kg); abciximab plus standard-dose, weight-adjusted hep-
rin; or abciximab plus a reduced-dose, weight-adjusted
eparin (70 U/kg bolus, activated clotting time [ACT] goal
00 to 300 s) regimens. Although rates of 30-day composite
schemic events were reduced by 56% in both abciximab
roups, bleeding was increased only in the abciximab plus
tandard-dose heparin group (2). In the ESPRIT trial,
IMI major bleeding was overall increased with eptifibatide
herapy, but not in the tertile of patients with ACT 244 s
44). Later trials using low-dose heparin, early sheath
emoval, avoidance of routine placement of venous sheaths,
nd target ACT levels of 200 to 250 s reported no difference
n major or minor bleeding for patients treated with abcix-
mab versus placebo (3,7). This highlights the efficacy and
afety of GPI when used in conjunction with a reduced-dose
eparin regimen and a target ACT of 200 s.
pstream Versus Downstream Administration
f GPI in ACS
arly GPI studies have suggested that the upstream use of
PI in ACS reduces the risk of MI in the pre-procedural
eriod compared with therapy with heparin only (5,7,8).
ecently, however, in the EARLY ACS (Early Glycopro-
ein IIb/IIIa Inhibition in Non–ST-Segment Elevation
cute Coronary Syndromes) trial, the routine upstream
ddition of eptifibatide to the therapy of intermediate- and
igh-risk NSTE-ACS patients managed with an intended
nvasive strategy did not prove superior to their provisional
ownstream addition during PCI and was associated with
n increase in bleeding (45). This may be in part explained
y the fact that any anti-ischemic benefit conferred during
he time interval preceding PCI is offset by a 2.4% increase
n TIMI major or minor bleeding, and that patients
ssigned an invasive strategy did not always undergo PCI. In
act, the upstream use of GPI significantly reduced the
bsolute risk of ischemic events by 2.4% in patients who
nderwent PCI. Furthermore, in the FINESSE (Facilitated
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1216ntervention With Enhanced Reperfusion Speed to Stop
vents) trial, the early (“facilitated”) use of abciximab in
T-segment elevation MI before primary PCI, as opposed
o its use during PCI, did not translate into clinical benefit,
ut did increase major bleeding (46). Thus, in the current
ra of thienopyridine therapy, the upstream administration
f GPI in NSTE-ACS and STEMI is associated with
ncreased bleeding risk and may not be warranted on a
outine basis. However, GPI may still be used upstream in
atients with positive cardiac markers who are not loaded
ith clopidogrel and who are judged clinically to be at high
isk of thrombotic events relative to bleeding risk (i.e.,
efractory or recurrent ischemic chest pain), as proposed by
he American College of Cardiology guidelines (27). Fur-
her analysis of the EARLY ACS trial could help determine
ubgroups of patients that may benefit from upstream use of
PI.
adial Versus Femoral Approach:
ccess Management
emoral access site bleeding complications constitute over
ne-half of the major bleeding that occurs after PCI (as
Figure 1. Recommended Strategy of GPI Use in Patients Undergoing PCI a
Flow chart of the recommended strategy for glycoprotein IIb/IIIa inhibitor use
treated with stenting and thienopyridines. *Non–ST-segment elevation myocar
factors is associated with an increased bleeding risk: age  75 years, female, c
cardiogenic shock, or class IV heart failure. Also, adjust unfractionated heparin
U/kg and achieve a target activated clotting time of low 200 s. †The need for
timing of thienopyridine load. Adjust infusion dose to renal function. GPI  gl
thienopyridine.emonstrated in the EPIC, CAPTURE [Chimeric 7E3 antiplatelet Therapy in Unstable Angina Refractory to
tandard Treatment], REPLACE-2, and ACUITY trials)
1,5,23,24). Recent data from the NCDR-CathPCI registry
ndicates that, although used in a small minority of PCI
rocedures, the radial artery access site, compared with the
emoral artery access site, is associated with a 58% reduction
f bleeding and vascular complications (47). This benefit is
ore pronounced in elderly patients and in women. These
ndings have been replicated in several registry analyses, 1
f which suggests that the radial approach is associated with
significant reduction in mortality (48). An ongoing
ulticenter randomized trial that is an extension of the
URRENT–OASIS 7 (Clopidogrel Optimal Loading
ose Usage to Reduce Recurrent Events–Organization
o Assess Strategies in Ischemic Syndromes) study is
omparing the transradial and the transfemoral access
ites in patients with ACS undergoing PCI.
Importantly, this reduction in access site bleeding may
ttenuate the increase in bleeding risk associated with GPI.
recent analysis from the ACUITY trial reported that the
se of bivalirudin monotherapy was associated with signif-
cantly less 30-day major bleeding than heparin plus GPI
utinely Treated With Stenting and Thienopyridines
ients undergoing percutaneous coronary intervention and who are routinely
farction (18). #The presence of 1 and particularly 2 or more of the following
kidney disease stage 3 or worse, baseline anemia, history of prior bleeding,
during percutaneous coronary intervention: use a starting bolus dose of 50
t infusion after percutaneous coronary intervention (2 h) depends on the
tein IIb/IIIa inhibitor(s); PCI  percutaneous coronary intervention; thieno nd Ro
in pat
dial in
hronic
dose
a shor
ycoprofter femoral access (3.0% vs. 5.8%, p  0.0001), but not
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1217fter radial access (4.2% vs. 2.2%, p  0.19) (49). In a large
talian registry of patients who underwent PCI for ACS
tilizing GPI, the transradial approach, in comparison with
he transfemoral approach, was associated with low bleeding
ates and a 6.6 lower odds of major/minor bleeding (50).
hese results confirm the findings of an analysis of 150
atients undergoing PCI and receiving GPI: no major
ccess site bleeding complications occurred in the radial
roup (51). The radial approach may be particularly useful
n women or high-bleeding risk patients receiving GPI.
urthermore, as opposed to transfemoral PCI, female sex
as not a predictor of adverse clinical outcomes after
ransradial PCI performed under maximal antiplatelet ther-
py, including GPI (52).
If, by contrast, transfemoral access is used, early sheath
emoval within 4 to 6 h of the procedure seems fundamental
n reducing bleeding risk (1,2,5). Though the reduction of
ascular complications with vascular closure devices remains
uestionable, early sheath removal allowed by these devices
ay prove beneficial. A multivariate analysis from the
CDR-CathPCI registry showed that closure devices were
ignificantly associated with less bleeding and vascular
ccess complications (53). In addition, closure devices have
een reported to be safe in patients receiving GPI (54). A
ecent analysis of the ACUITY trial data showed that
ascular closure devices independently reduce access site
leeding by 22%; this benefit extended to patients receiving
PI (55). It is important to point out that these analyses are
bservational and that the safety and potential benefit may
e driven by the operator’s experience with these devices.
Collectively, available data support the use of the radial
ccess site, smaller sheaths (irrespective of the access site),
rompt sheath removal, and possibly vascular closure de-
ices to minimize bleeding risk, although additional pro-
pective and/or randomized data are needed in some of
hese areas.
In summary, we suggest a strategy of GPI use that takes
nto account the patient’s baseline ischemic and bleeding
isk and the above-described measures limiting hemorrhagic
vents (Fig. 1). Many ischemic risk factors are also bleeding
isk factors (56,57), hence the importance of a careful use of
PI with the strategies outlined in Table 5.
onclusions and Final Recommendations
Early studies have shown a reduction of ischemic events
with GPI, yet more recent studies performed in the era of
routine thienopyridine therapy show an increase in
bleeding risk and a less consistent net clinical benefit of
GPI administration.
To use GPI safely, one should:X Target high-risk patients, particularly NSTEMI pa-
tients or patients undergoing PCI without adequate
clopidogrel pre-loading.
X Avoid the routine upstream use of GPI in ACS,
particularly if thienopyridines are used early on.
X Appropriately adjust dose for patients with renal
failure.
X Reduce or eliminate the infusion.
X Use radial approach, particularly in patients with
NSTEMI who otherwise have an indication to re-
ceive GPI.
X Select lower bleeding risk patients, which is challeng-
ing because ACS patients who are likely to benefit
from GPI have a higher bleeding risk than stable
patients (56,57).
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